Lesage Anne 4
4 · Pharvaris N.V. · Filed Jul 1, 2026
Research Summary
AI-generated summary of this filing
Pharvaris (PHVS) Anne Lesage Exercises Options and Sells Shares
What Happened
- Anne Lesage, Chief Early Development at Pharvaris (PHVS), exercised stock options and sold shares on June 29–30, 2026. She exercised a total of 38,472 option-derived shares (multiple option tranches) and paid roughly $263,442 in aggregate exercise price. She sold a total of 76,172 shares in open‑market/cashless transactions for about $2.70 million (aggregate ≈ $2,695,453).
Key Details
- Transaction dates: June 29–30, 2026; Form 4 filed July 1, 2026 (appears filed timely).
- Exercise details (selected): multiple exercises at strike prices $2.59 and $8.05 (examples: 24,900 shares @ $8.05; 4,200 @ $2.59; several smaller tranches).
- Sales: weighted average sale prices reported around $35.05–$35.49; per-footnotes the sale price ranges across trades were approximately $35.00 to $35.86. Total cash received from reported sales ≈ $2.7M.
- Shares owned after transaction: not specified in the summary data provided in this request (check full Form 4 for post‑transaction beneficial ownership).
- Notable footnotes: sales were made pursuant to a Rule 10b5‑1 trading plan (scheduled exercises/sales, F1/F5). Several footnotes (F2–F6, F8) state the reported sale prices are weighted averages across multiple trades and that shares were sold in connection with cashless option exercises. Vesting schedules for options noted in F10 and F9.
- Reporting entity note: footnote references an entity controlled by Lesage (GrayMatters Consulting B.V., F7) in the filing.
Context
- These transactions are option exercises (derivative code M) followed by sales—many were cashless exercises where exercised shares were sold immediately under a pre‑arranged 10b5‑1 plan. That means Lesage converted options into shares and sold shares according to a scheduled plan rather than open, discretionary trades.
- For retail investors: exercises followed by immediate sales are often routine (to cover exercise costs and taxes) and do not necessarily signal a change in insider conviction. Purchases would typically be more informative about bullish insider sentiment.
Insider Transaction Report
Form 4
Pharvaris N.V.PHVS
Lesage Anne
Chief Early Development
Transactions
- Exercise/Conversion
Common Stock
[F1]2026-06-29$2.59/sh+1,400$3,626→ 57,850 total - Exercise/Conversion
Common Stock
[F1]2026-06-29$8.05/sh+900$7,245→ 58,750 total - Exercise/Conversion
Common Stock
[F1]2026-06-29$2.59/sh+4,100$10,619→ 56,450 total - Exercise/Conversion
Common Stock
[F1]2026-06-29$8.05/sh+4,200$33,810→ 67,050 total - Sale
Common Stock
[F1][F2]2026-06-29$35.12/sh−2,300$80,786→ 56,450 total - Sale
Common Stock
[F1][F3]2026-06-29$35.05/sh−8,300$290,908→ 58,750 total - Exercise/Conversion
Common Stock
[F1]2026-06-30$2.59/sh+2,972$7,697→ 61,722 total - Exercise/Conversion
Common Stock
[F1]2026-06-30$8.05/sh+24,900$200,445→ 86,622 total - Sale
Common Stock
[F1][F4]2026-06-30$35.48/sh−27,872$988,890→ 58,750 total - Sale
Common Stock
[F5][F6][F7]2026-06-29$35.05/sh−6,997$245,232→ 124,672 total(indirect: By GrayMatters Consulting BVBA) - Sale
Common Stock
[F5][F8][F7]2026-06-30$35.49/sh−30,703$1,089,637→ 93,969 total(indirect: By GrayMatters Consulting BVBA) - Exercise/Conversion
Stock Option (Right to Buy)
[F1][F9]2026-06-29−4,200→ 69,900 totalExercise: $8.05Exp: 2033-04-06→ Common Stock (4,200 underlying) - Exercise/Conversion
Stock Option (Right to Buy)
[F1][F9]2026-06-30−24,900→ 45,000 totalExercise: $8.05Exp: 2033-04-06→ Common Stock (24,900 underlying) - Exercise/Conversion
Stock Option (Right to Buy)
[F1][F10]2026-06-29−1,400→ 7,072 totalExercise: $2.59Exp: 2030-01-01→ Common Stock (1,400 underlying) - Exercise/Conversion
Stock Option (Right to Buy)
[F1][F10]2026-06-29−4,100→ 2,972 totalExercise: $2.59Exp: 2030-01-01→ Common Stock (4,100 underlying) - Exercise/Conversion
Stock Option (Right to Buy)
[F1][F10]2026-06-30−2,972→ 0 totalExercise: $2.59Exp: 2030-01-01→ Common Stock (2,972 underlying)
Footnotes (10)
- [F1]This is a scheduled exercise and sale from 10b5-1 trading plan.
- [F10]25% of the option vested on January 1, 2021 with the remaining shares vesting in 1/48 monthly installments thereafter.
- [F2]The reported price represents a weighted average sale price for shares sold in multiple transactions on the reported date pursuant to a Rule 10b5-1 trading plan. The shares were sold in connection with the exercise of stock options in a cashless exercise transaction. The sales prices for the transactions ranged from $35.00 to $35.30. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.
- [F3]The reported price represents a weighted average sale price for shares sold in multiple transactions on the reported date pursuant to a Rule 10b5-1 trading plan. The shares were sold in connection with the exercise of stock options in a cashless exercise transaction. The sales prices for the transactions ranged from $35.00 to 35.12. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.
- [F4]The reported price represents a weighted average sale price for shares sold in multiple transactions on the reported date pursuant to a Rule 10b5-1 trading plan. The shares were sold in connection with the exercise of stock options in a cashless exercise transaction. The sales prices for the transactions ranged from $35.00 to $35.84. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.
- [F5]This is a scheduled sale from 10b5-1 trading plan.
- [F6]The reported price represents a weighted average sale price for shares sold in multiple transactions on the reported date pursuant to a Rule 10b5-1 trading plan. The sales prices for the transactions ranged from $35.00 to $35.12. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.
- [F7]GrayMatters Consulting B.V., an entity controlled by Dr. Lesage
- [F8]The reported price represents a weighted average sale price for shares sold in multiple transactions on the reported date pursuant to a Rule 10b5-1 trading plan. The sales prices for the transactions ranged from $35.00 to $35.86. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.
- [F9]25% of the option vested on April 6, 2024 with the remaining shares vesting in 1/48 monthly installments thereafter.
Signature
/s/ Marnus Nel, Attorney-in-Fact for Anne Lesage|2026-07-01